Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSF
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroblastoma
Conditions
Neuroblastoma
Trial Timeline
Dec 16, 2024 → Dec 1, 2038
NCT ID
NCT06450041About Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSF
Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSF is a phase 2 stage product being developed by United Therapeutics for Neuroblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06450041. Target conditions include Neuroblastoma.
What happened to similar drugs?
0 of 1 similar drugs in Neuroblastoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06450041 | Phase 2 | Recruiting |
Competing Products
20 competing products in Neuroblastoma